ATS 2024 Final Program

Click on the session title to view the speakers

269

TUESDAY • MAY 21

P1048 An Unusual Case of Chest Pain in a Young Woman P1049 Acute Gastrointestinal Bleed Unmasks Rare Cause for Elevated A-a Gradient P1050 An Unusual Case of Asthma P1051 Hemoptysis and a Hole in the Heart; When Uncommon Becomes Extraordinary P1052 A Rare Case of Hemoptysis During Sexual Intercourse P1053 Apical Hypertrophic Cardiomyopathy, an Initial Encounter Highlighting Need for Broader Approach to Screening P1054 A Rare Encounter: Unveiling May-Thurner Syndrome Amidst a Complex Clinical Scenario P1055 A Rare Case of Pulmonary Arterial Sarcoma C62 TOP GUN: NOVEL THERAPEUTICS AND OUTCOMES IN PAH 9:15 a.m. - 4:15 p.m. Viewing: Posters will be on display for entire session Discussion: 11:30-12:30 Discussionwith facilitators, authors, andattendees 12:30-1:15 Authorswill beby their posters for individual discussionwithattendees P259 Longitudinal Hemodynamic Response and Clinical Outcomes in Portopulmonary Hypertension P260 Low Plasma Serotonin Levels Are Associated With Decreased Exercise Capacity in Long-COVID Patients During ICPET P261 Factors Associated With Higher or Lower Risk of Receiving a Transplant in Pulmonary Hypertension Subtypes: Insights From the National Inpatient Sample P262 Exploring Variations and Outcomes Among Pulmonary Hypertension Subtypes: Insights From the National Inpatient Sample San Diego Convention Center Area C (Hall A-B2, Ground Level) CLINICAL • TRANSLATIONAL THEMATIC POSTER SESSION

P263 Pre-planned Study Design Adaptations in UNISUS: A Phase 3, Randomized Superiority Study Comparing the Efficacy, Safety, and Tolerability of Macitentan 75 Mg Versus 10 Mg in Patients With Pulmonary Arterial Hypertension (PAH) P264 Pulmonary Arterial Compliance Is an Important Predictor of Post-transplant Survival Among Kidney Transplant Recipients P265 MELD-Na Can Predict the Severity of Pulmonary Arterial Hypertension P266 Determinants of Estimated Glomerular Filtration Rate in Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension P267 Baseline Characteristics From the IMPAHCT Trial of AV-101, Inhaled Imatinib, in Subjects With Pulmonary Arterial Hypertension P268 Phenotypic Drift in Patients With Pre-capillary Pulmonary Hypertension P269 Predicting Pre-capillary Pulmonary Hypertension in Systemic Sclerosis by Regional Longitudinal Strain Patterns on Echocardiography P270 Provider Preferences Regarding the Use of Combination ERA+PDE5i for the Treatment of Pulmonary Arterial Hypertension: Results From a Discrete Choice Experiment P271 Blood Pressure Change During Six-minute Walk Test Is an Independent Predictor of Clinical Worsening in Patients With Pulmonary Hypertension P272 Efficacy of Specific Drug Class Therapy in Pulmonary Arterial Hypertension Associated With HIV, Portal Hypertension or Both: A Single Center Experience P273 Identification of Inflammatory Cells in the Sex Dimorphism of Pulmonary Arterial Hypertension P274 Pulmonary Hypertension in HIV and Heart Failure: Clinical Insights and Survival Outcomes P275 Number of Attempts and Interventions Needed to Adequately Measure the Pulmonary Artery Wedge Pressure During Right Heart Catheterization P276 Alterations in ECG in PAH Patients Who Died From Sudden Death Compared With Right Heart Failure

ATS 2024 Conference Program • San Diego, CA